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Introduction {#sec1}
============

Gliomas are the most common primary malignant tumors of the central nervous system (CNS) with different grades of malignancy where grade II is the lowest and grade IV is the highest ([@bib19]). The growth pattern of gliomas is characterized by diffuse tumor growth and tumor cell invasion resulting in tumor microsatellites growing far away from the main tumor mass ([@bib14]). Diffuse (grade II) and anaplastic (grade III) gliomas are infiltrative neoplasms that most often arise in cerebral hemispheres of adults and include astrocytomas and oligodendrogliomas ([@bib28]). Grade II and III astrocytomas are generally characterized by the IDH1-R132H mutation, whereas oligodendrogliomas are IDH1 mutated and 1p and 19q co-deleted ([@bib19]). The latter show better responses to radiochemotherapy and are associated with longer survival than IDH1 wild-type diffuse gliomas or grade IV gliomas denoted glioblastomas (GBMs) ([@bib6], [@bib11], [@bib44]). Conventional therapy for GBMs includes maximal safe surgical resection followed by radiation with concomitant and adjuvant temozolomide treatment that prolongs survival but is not curative ([@bib38]). There is thus an immediate need to develop alternative therapies for GBMs.

There are several cell types in the tumor microenvironment that contribute to glioma malignancy, e.g., astrocytes, endothelial cells, pericytes, and immune cells, including tumor-associated macrophages and microglia (TAMMs) ([@bib37]). Interestingly, almost half of the tumor mass may consist of TAMMs in both murine as well as human gliomas ([@bib15]), and the accumulation of TAMMs is associated with poor clinical outcome in gliomas ([@bib7], [@bib41]). In platelet-derived growth factor (PDGFB)-driven glioma the majority of TAMMs is of a pro-tumoral phenotype, and the reprogramming of these TAMMs toward an anti-tumoral phenotype hampers PDGFB-driven glioma growth ([@bib35], [@bib36]).

PDGFB can bind to both PDGFRA and PDGFRB and is known to play multiple roles in tumor development, both in the tumor cells themselves and within the microenvironment ([@bib25]). However, in the RCAS-induced gliomas, it has been postulated that PDGFB drives tumor initiation and progression mainly by activating PDGFRA on nestin^+^ glial cells ([@bib5], [@bib17], [@bib43]). In concordance, large-scale integrated molecular analyses of GBMs have shown that a subset of these tumors are driven by activation of the PDGFRA signaling pathway ([@bib4], [@bib45]), and this has also been confirmed by computational and experimental modeling ([@bib34]). The expression of PDGFRB on tumor cells has been less studied, although one study reports that PDGFRB can be expressed in cultured patient-derived GBM cells, particularly in the cancer stem-cell-like population ([@bib26]).

Herein we demonstrated that PDGFRB was expressed on glioma cells (GCs) in mouse and human gliomas in proximity to TAMMs. Both PDGFRB expression on GCs and TAMM accumulation were significantly increased in high-grade gliomas (HGGs) compared with low-grade gliomas (LGGs). Mechanistic studies showed that M2-polarized microglia, but not M2-polarizied bone marrow-derived macrophages (BMDMs), induced GCs to acquire PDGFRB expression and augmented their migratory capacity. In summary, we propose a new mechanism whereby GC migratory behavior may be modulated.

Methods can be found in Transparent Methods in the [Supplemental Information](#appsec2){ref-type="sec"}.

Results {#sec2}
=======

PDGFB-Driven Gliomas in the *N/tv-a;Arf*^*−/−*^ Mouse Model Display Necrosis, Hypoxia, and Vessel Hyperproliferation Similarly to Human Gliomas {#sec2.1}
-----------------------------------------------------------------------------------------------------------------------------------------------

Studies in transgenic mice indicate that gliomas can arise from a range of cell types including neural stem cells, astrocytes, oligodendrocytes, or glial progenitor cells ([@bib23], [@bib27]). We investigated the role of TAMMs in the *N/tv-a;Arf*^*−/−*^ mouse model in which the retrovirus will specifically transform glial stem and progenitor cells resulting in glioma development between 1 to 3 months ([@bib24], [@bib42]). According to histopathological characteristics (evaluated by neuropathologist H. Miletic) the tumors were divided into human grade II-, grade III- and grade IV-like gliomas, where grade IV-like gliomas displayed necrotic areas ([Figure 1](#fig1){ref-type="fig"}A). GCs and glioblastoma stem cells (GSCs) in particular express OLIG2 ([@bib29]), which in the normal brain is restricted to oligodendroglial cells and their progenitors ([@bib31]). Gliomas that display OLIG2^+^GCs that have acquired the expression of the glial fibrillary acidic protein (GFAP), which defines differentiated astrocytes, are generally classified as astrocytomas ([@bib32]), whereas OLIG2^+^GCs that are negative for GFAP are typically classified as oligodendrogliomas that can never develop into a grade IV glioma ([@bib19]). Importantly, all the PDGFB-driven grade II-, grade III-, and grade IV-like gliomas displayed OLIG2^+^GFAP^+^GCs ([Figure 1](#fig1){ref-type="fig"}B), indicating that these tumors are low- or high-grade astrocytomas rather than oligodendrogliomas ([@bib40]).Figure 1PDGFB-Driven Gliomas in the *N/tv-a;Arf*^*−/−*^ Mouse Model Display Necrosis and Decreased Vessel Perfusion(A) Images display tumor sections immunostained with H&E. Scale bars, 200 μm.(B) Glioma sections were immunostained for OLIG2 (green) and GFAP (red). Scale bars, 50 μm.(C--G) (C) Images display tumors perfused with fluorescein isothiocyanate-conjugated lectin (green) and immunostained for the endothelial marker CD31 (blue). Graphs display (D) vessel area, (E) vessel density, (F) area of perfused vessels, and (G) % number of perfused vessels. (n = 3--5). Scale bars, 100 μm. Statistical analysis: one-way ANOVA was used; \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001; \* indicates significance compared with grade II-like tumors; ^\#^p \< 0.05; ^\#^ indicates significance between grade III- and grade IV-like tumors.

Tumor necrosis is associated with poorly perfused abnormal vessels with proliferative endothelial cells, resulting in an inadequate supply of the tumor with oxygen and nutrients ([@bib21]). Increased vessel area, decreased vessel perfusion, and hypoxia generally indicate vessel abnormalization that correlates with tumor malignancy ([@bib30], [@bib39]). Hence, we next performed morphometric analysis for CD31 (endothelial cell marker) and fluorescein isothiocyanate-conjugated lectin, which detects perfused vessels ([Figure 1](#fig1){ref-type="fig"}C), or pimonidazole hydrochloride staining, which identifies hypoxic areas ([Figure 2](#fig2){ref-type="fig"}A). Both vessel area ([Figures 1](#fig1){ref-type="fig"}C and 1D) and vessel density ([Figures 1](#fig1){ref-type="fig"}C and 1E) were evidently increased between grade II- and grade III-like gliomas, and between grade II- and grade IV-like gliomas. Consistently, vessel perfusion ([Figures 1](#fig1){ref-type="fig"}C, 1F, and 1G) was markedly decreased, whereas hypoxia ([Figures 2](#fig2){ref-type="fig"}A and 2B) was increased in grade III- and grade IV-like gliomas compared with grade II-like gliomas. These features suggested that most of the vessels in the grade II-like gliomas are co-opted, non-angiogenic vessels ([@bib16]). In corroboration, endothelial cells in grade II-like gliomas displayed significantly less proliferation compared with grade III- and grade IV-like gliomas as visualized by staining of tumor sections for podocalyxin and Ki67 ([Figures 2](#fig2){ref-type="fig"}C and 2D).Figure 2PDGFB-Driven Gliomas in the *N/tv-a;Arf*^*−/−*^ Mouse Model Display Hypoxia and Vessel Hyperproliferation(A and B) (A) Glioma sections were immunostained for CD31 (blue), fluorescein isothiocyanate (FITC)-conjugated lectin (green), and the hypoxic marker pimonidazole (PIMO; red). (B) Graph shows morphometric analysis of hypoxic areas (n = 3--5). Scale bars, 100 μm.(C and D) (C) Glioma sections were immunostained for podocalyxin (green) and Ki67 (red). (D) Graph depicts quantification of podocalyxin^+^Ki67^+^ vessels (n = 3). Scale bars, 100 μm.(E and F) (E) Glioma sections were immunostained for CD31 (blue), FITC-conjugated lectin (green), and the pericyte marker α-SMA (red). (F) Graph displays quantification of α-SMA (n = 3--5). Scale bars, 100 μm.(G and H) (G) Glioma sections were immunostained for OLIG2 (blue), FITC-conjugated lectin (green), and α-SMA (red). (H) Graph shows analysis of α-SMA^+^ sheets associated with vessels. Scale bars, 100 (left panel) and 50 (right panel) μm.(I) Glioma sections were immunostained for podocalyxin (blue), microglia marker IBA1 (green), and α-SMA (red). Scale bars, 100 (left panel) and 50 μm (right panel).Statistical analysis: one-way ANOVA (A--F) and student\'s t test (G and H) were used: \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001; \* indicates significance (A--F) compared with grade II-like tumors and (H) between α-SMA^+^ sheets associated and non-associated with vessels; ^\#^p \< 0.05; ^\#^ indicates significance between grade III- and grade IV-like tumors.

Displacement of pericytes covering the tumor vessels is yet another hallmark of vessel abnormalization and dysfunctionality ([@bib2], [@bib30]). Tumor sections were therefore stained for OLIG2, CD31, and the pericyte marker α-smooth muscle actin (α-SMA). The accumulation of α-SMA^+^ cells was profoundly increased with the degree of malignancy ([Figures 2](#fig2){ref-type="fig"}E and 2F). Surprisingly, the majority of the α-SMA^+^ cells were not found in conjugation with perfused vessels ([Figures 2](#fig2){ref-type="fig"}G and 2H) and were instead in close association with IBA1^+^ TAMMs ([Figure 2](#fig2){ref-type="fig"}I).

Glioma Cells Express Pericyte Markers in Mouse and Human Gliomas {#sec2.2}
----------------------------------------------------------------

To investigate whether the α-SMA^+^ cells were indeed bona fide pericytes, grade IV-like gliomas were stained for the pericyte markers PDGFRB and NG2 (that also stains oligodendrocyte progenitor cells). The majority of the α-SMA^+^ cells that appeared in sheets did indeed express PDGFRB ([Figure 3](#fig3){ref-type="fig"}A) and NG2 ([Figure 3](#fig3){ref-type="fig"}B), and a portion of these cells also expressed the mesenchymal marker CD44 ([Figure 3](#fig3){ref-type="fig"}C), but were negative for GC and GSC markers including SOX2 ([Figure 3](#fig3){ref-type="fig"}D), OLIG2 ([Figure 3](#fig3){ref-type="fig"}E), and GFAP ([Figure 3](#fig3){ref-type="fig"}F). Intriguingly, α-SMA^+^ cells that appeared as round cells did indeed express GC and GSC markers including SOX2 ([Figure 3](#fig3){ref-type="fig"}D), OLIG2 ([Figure 3](#fig3){ref-type="fig"}E), and GFAP ([Figure 3](#fig3){ref-type="fig"}F). Importantly, these α-SMA^+^ cells also expressed the hemagglutinin (HA) tag, which can only be expressed by the initial RCAS-infected nestin-expressing glial cells ([Figure 3](#fig3){ref-type="fig"}G). The round α-SMA^+^SOX2^+^, α-SMA^+^OLIG2^+^, α-SMA^+^GFAP^+^, and α-SMA^+^HA^+^ cells accounted for ∼20% of the total α-SMA population in grade IV-like gliomas ([Figure 3](#fig3){ref-type="fig"}H).Figure 3Glioma Cells Express Pericyte Markers in Mouse Gliomas(A--H) Mouse glioma sections were immunostained for (A) α-SMA (red) and the pericyte marker PDGFRB (green), (B) α-SMA (red) and the pericyte and oligodendrocyte marker NG2 (blue), (C) α-SMA (red) and the mesenchymal and stem cell marker CD44 (green), (D) α-SMA (red) and the GSC marker SOX2 (green), (E) α-SMA (red) and the oligodendrocyte marker OLIG2 (green), (F) α-SMA (red) and the astrocyte marker GFAP (green), and (G) α-SMA (red) and the HA tag expressed by PDGF-B-transformed cells (green). Left panels show α-SMA^+^ sheets, whereas right panels display round α-SMA^+^ cells. Scale bars, 100 (left panel) and 50 (right panel) μm. (H) Graph displays quantification of HA^+^, OLIG2^+^, SOX2^+^, and GFAP^+^ cells out of α-SMA^+^ cells (n = 3).Statistical analysis: one-way ANOVA was used.

Spatial Location of αSMA^+^PDGFRB^+^GCs in Mouse and Human Gliomas {#sec2.3}
------------------------------------------------------------------

It has previously been proposed that GSCs can give rise to perivascular pericytes ([@bib8]) and are located in the vicinity of tumor vessels. However, here we find that α-SMA^+^ OLIG2^+^ ([Figure 4](#fig4){ref-type="fig"}A), α-SMA^+^SOX2^+^ ([Figure 4](#fig4){ref-type="fig"}B), and α-SMA^+^PDGFRB^+^ cells ([Figure 4](#fig4){ref-type="fig"}C) are scattered throughout the tumor mass and are not located perivascularly. Our observation that α-SMA^+^GCs rarely attached to vessels led us to investigate if these α-SMA^+^GCs were associated with other types of stromal cells such as TAMMs that accumulate in HGGs ([@bib35], [@bib36]). Indeed, IBA1^+^ TAMMs were closely associated with α-SMA^+^HA^+^ ([Figure 4](#fig4){ref-type="fig"}D) and PDGFRB^+^HA^+^ ([Figure 4](#fig4){ref-type="fig"}E) cells in mouse HGGs. Of note, α-SMA^+^IDH1-R132H^+^ cells were also in close proximity to IBA1^+^ TAMMs in human HGGs ([Figure S1](#mmc1){ref-type="supplementary-material"}). We then speculated that PDGFRB^+^GCs might correlate to the accumulation of TAMMs in mouse and human gliomas. Indeed, PDGFRB^+^HA^+^ ([Figures 5](#fig5){ref-type="fig"}A--5E), PDGFRB^+^IDH1-R132H^+^, and PDGFRB^+^GFAP^+^ cells correlated to TAMM accumulation ([Figures 5](#fig5){ref-type="fig"}F--5J). In fact, ∼70% of PDGFRB^+^GCs in grade III- and grade IV-like mouse gliomas ([Figure 5](#fig5){ref-type="fig"}E) and human GBMs ([Figure 5](#fig5){ref-type="fig"}J) were in physical contact with IBA1^+^ TAMMs. It has recently been revealed that the transcription factor Sall1 is preferentially expressed by microglia and not macrophages ([@bib48]). In fact, the majority of IBA1^+^ TAMMs expressed Sall1 ([Figure S2](#mmc1){ref-type="supplementary-material"}A) and not CD49d ([Figure S2](#mmc1){ref-type="supplementary-material"}B), which is preferentially expressed by macrophages, indicating that these cells were microglia and not macrophages. In summary, the spatial location of TAMM accumulation strongly correlated with α-SMA^+^ and PDGFRB^+^GCs.Figure 4Spatial Location of α-SMA^+^SOX2^+^, α-SMA^+^OLIG2^+^, and α-SMA^+^PDGFRB^+^ GCs in Mouse Gliomas(A--C) Mouse glioma sections were immunostained for (A) OLIG2 (blue), α-SMA (red), and podocalyxin (green); (B) SOX2 (blue), α-SMA (red), and podocalyxin (green); and (C) PDGFRB (blue), α-SMA (red), and podocalyxin (green). Scale bars, 100 μm.(D) Mouse grade IV-like glioma sections were immunostained for HA tag (expressed by PDGFB-transformed cells; blue), α-SMA (red), and IBA1 (green). Scale bars, 50 μm.(E) Mouse grade IV-like glioma sections were immunostained for HA tag (blue), PDGFRB (red), and IBA1 (green). Scale bars, 50 μm.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.Figure 5Glioma Cells Express PDGFRB and Correlate with IBA1^+^ TAMMs in Mouse and Human Gliomas(A--E) (A) Mouse glioma sections were immunostained for H&E, HA tag (green/blue), PDGFRB (red), and IBA1 (green). Graphs display (B) number of PDGFRB^+^HA^+^ cells out of HA^+^ cells, (C) area of IBA1^+^ cells, (D) Pearson\'s correlation between PDGFRB^+^ cells versus area of IBA1, and (E) number of PDGFRB^+^HA^+^ cells in contact with IBA1^+^ cells (n = 3--5). Scale bars 200 (left panel), 50 (middle panel), and 20 (far right panel) μm.(F--J) (F) Human glioma sections were immunostained for IDH1-R132H or GFAP (blue), PDGFRB (red), and IBA1 (green). Graphs depict (G) number of PDGFRB^+^IDH1-R132H^+^ cells or PDGFRB^+^GFAP^+^ cells out of IDH1-R132H^+^ or GFAP^+^ cells, (H) area of IBA1^+^ cells, (I) Pearson\'s correlation between PDGFRB^+^ cells versus area of IBA1, and (J) number of PDGFRB^+^IDH1-R132H^+^ or PDGFRB^+^GFAP^+^ cells in contact with IBA1^+^ cells (n = 5--6). Scale bars, 50 (left panel) and 20 (far right panel) μm.Statistical analysis: one-way ANOVA (B, C, E, G, H, and J) and Pearson\'s correlation (D and I) were used: \*p \< 0.05, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001; \* indicates significance compared with grade II-like tumors; ^\#\#\#^p \< 0.001, ^\#\#\#\#^p \< 0.0001; ^\#^ indicates significance between grade III- and grade IV-like tumors. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

TAMMs Induce Mouse Glioma Cells to Express PDGFRB {#sec2.4}
-------------------------------------------------

We hypothesized that pro-tumoral TAMMs could drive tumor cells to express *pdgfrb* due to their spatial localization. Thus, microglia derived from adult mice polarized to an M1-phenotype (lipopolysaccharide \[LPS\] and interferon \[IFN\]-γ) or an M2 phenotype (interleukin \[IL\]-4, IL-10, and transforming growth factor \[TGF\]-β) *in vitro* were co-cultured with GFP^+^GSCs derived from grade IV-like PDGFB-induced tumors in *N/tv-a;Arf*^−/-^ mice. As expected, qPCR analysis showed that M1-polarized microglia displayed high gene expression levels of chemokine (C-X-C motif) ligand (*cxcl*)*9*, *cxcl10*, *cxcl11*, *il*-*6,* and *il-1β*, whereas M2-polarized microglia showed high expression levels of *arginase 1*, *mrc1,* and *ym1* ([Figure 6](#fig6){ref-type="fig"}A). Interestingly, GFP^+^GSCs flow sorted from the co-culture system displayed induced levels of *pdgfrb* ([Figure 6](#fig6){ref-type="fig"}B) and increased levels of *α-sma* transcription levels (30-fold; [Figure 6](#fig6){ref-type="fig"}C) in the presence of M2-polarized microglia. Surprisingly, co-culture with M1-polarized microglia also induced *pdgfrb* expression ([Figure 6](#fig6){ref-type="fig"}B) and increased *α-sma* levels ([Figure 6](#fig6){ref-type="fig"}C), but significantly less compared with M2 microglia. Importantly, basal expression of *pdgfrb* was undetectable. Notably, *pdgfra* was not affected by either M1- or M2-polarized microglia ([Figure 6](#fig6){ref-type="fig"}D).Figure 6TAMMs Induce Mouse Glioma Cells to Express PDGFRB(A) Microglia were polarized to either an M1 or M2 phenotype. Graph shows gene expression levels of *cxcl9, cxcl10, cxcl11*, *il-6, il-1b*, *arginase1*, *mrc1, and ym1* analyzed by qRT-PCR (n = 3).(B--F) GFP^+^GSCs were co-cultured with M1- or M2-polarized microglia. Graphs depict qRT-PCR analysis of gene expression levels of flow-sorted tumor cells for (B) *pdgfrb*, (C) *α-sma*, (D) *pdgfra*, (E) *fgfr* and *igf-1r,* and (F) *egfr* and *hgfr* (n = 3).(G) GFP^+^GSCs were cultured with M0 (not polarized)-, M1- or M2-like microglia conditioned media. Graph displays gene expression levels for *α-sma* quantified by quantitative RT-PCR (n = 3).(H) GFP^+^GSCs were co-cultured with M1- or M2-polarized BMDMs. Graph shows qRT-PCR analysis of gene expression levels of flow-sorted tumor cells for *α-sma* (n = 3).(I--K) GFP^+^GSCs were co-cultured with M1- or M2-polarized microglia. Graphs depict quantitative RT-PCR analysis of gene expression levels of flow-sorted tumor cells for (I) *nestin*, *olig2,* and *sox2;* (J) *cnp, ng2,* and *hes1;* and (K) *gfap* (n = 3).(L and M) GFP^+^GSCs were co-cultured with M1- or M2-polarized microglia, and migrated tumor cells were stained for the OLIG2 marker. Graphs display (L) migrated tumor cells (n = 3) and (M) migrated tumor cells with isotype control or neutralizing PDGFRB antibody (n = 3).Statistical analysis: Student\'s t test (A) and one-way ANOVA (B--M) were used: \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001; \* indicates significance (B--L) compared with tumor cells alone, and (M) compared with tumor cells without PDGFRB blockage; ^\#^p \< 0.05, ^\#\#^p \< 0.01, ^\#\#\#^p \< 0.001, ^\#\#\#\#^p \< 0.0001; ^\#^ indicates significance between (A) M1-like and M2-like microglia and (B--L) tumor cells co-cultured with M1 microglia compared with M2 microglia and (M) tumor cells co-cultured with M2-like microglia without PDGFRB blockage compared with PDGFRB blockage. All data represent one out of three independent experiments and are presented as the mean +SD. See also [Table S1](#mmc1){ref-type="supplementary-material"}.

As GCs have been shown to express different tyrosine kinases, we next examined if M2-polarized microglia could alter the expression of a variety of tyrosine kinase receptors, including epidermal growth factor receptor (*egfr*), fibroblast growth factor receptor (*fgfr*), hepatocyte growth factor receptor (*hgfr*), or insulin-like growth factor-1 receptor (*igf-1r*). In fact, M1- and M2-polarized microglia did not affect the expression of *fgfr*, *igf-1r* ([Figure 6](#fig6){ref-type="fig"}E), *or hgfr* ([Figure 6](#fig6){ref-type="fig"}F). Even though M1- and M2-polarized microglia could induce *egfr* expression in GCs, the expression levels were about 100-fold less compared with that of *pdgfrb* ([Figure 6](#fig6){ref-type="fig"}F). We further explored if the expression of *pdgfrb* in GCs could also be modulated by microglia-secreted factors. GCs were thus cultured with control medium or conditioned medium from M1- or M2-polarized microglia. Interestingly, neither *pdgfrb* nor *α-sma* expression could be either induced or increased, respectively, in the presence of conditioned medium from either M1- or M2-polarized microglia ([Figure 6](#fig6){ref-type="fig"}G).

Recent studies report that microglia are not only ontologically different from BMDMs ([@bib13]) but also exhibit distinct activation states based on diverse gene and surface marker expression, implying different functions compared with BMDMs ([@bib3]). We therefore investigated if BMDMs were capable of inducing the expression of *pdgfrb* in GCs by co-culturing GFP^+^GSCs with either M1-BMDMs (treated with LPS and IFN-γ) or M2-polarized BMDMs (treated with IL-4, IL-10, and TGF-β). These BMDMs displayed the same repertoire of cytokines as M1- and M2-polarized microglia. Surprisingly, neither M1- nor M2-polarized BMDMs could induce *pdgfrb* or increase the *α-sma* expression in GCs ([Figure 6](#fig6){ref-type="fig"}H). Intriguingly, preconditioning of BMDMs with medium from primary microglia culture did not induce *pdgfrb* or increase *α-sma* expression in GCs either (data not shown).

In summary, only cell-to-cell contact with microglia could induce *pdgfrb* expression in GCs. We further explored if M1- or M2-polarized microglial cell-to-cell contact with GSCs could further alter their expression of glial, stem, and progenitor cell markers. Surprisingly, most glial stem cell and progenitor cell markers including *nestin*, *olig2*, *sox2* ([Figure 6](#fig6){ref-type="fig"}I), *ng2,* and *hes1* ([Figure 6](#fig6){ref-type="fig"}J) were not further modified by the presence of M1- or M2-polarized microglia. Interestingly, the marker for late oligodendrocyte precursor cells *cnp* ([@bib27]) ([Figure 6](#fig6){ref-type="fig"}J) was markedly decreased by both M1- and M2-polarized microglia, whereas the astrocytoma marker *gfap* ([Figure 6](#fig6){ref-type="fig"}K) was markedly increased by M2-polarized microglia. These findings indicate that regardless of the polarization state, microglia did not affect an overall increase in stem and progenitor cell markers.

In agreement with the notion that the PDGFRB signaling pathway is a key modulator in regulating cell migration ([@bib25]), we explored if M1- and M2-polarized microglia could affect the migration of cultured GCs. GFP^+^GSCs were therefore co-cultured with M1- or M2-polarized microglia before subjecting them to a Boyden chamber. Intriguingly, M2-polarized microglia fueled the migratory capacity of GCs ([Figure 6](#fig6){ref-type="fig"}L), whereas M1-polarized microglia significantly suppressed GC migration ([Figure 6](#fig6){ref-type="fig"}L). Blocking PDGFRB revoked the effect of M2-polarized microglia on tumor cell migration but had no effect on the M1-polarized-microglia-mediated inhibition of GC migration ([Figure 6](#fig6){ref-type="fig"}M). In summary, M2-polarized-microglia-stimulated migration of GCs was mediated by PDGFRB.

Discussion {#sec3}
==========

Herein we show that the presence of PDGFRB^+^GCs and α-SMA^+^GCs in mouse and human HGGs was tightly interlinked with the number of and physical proximity to TAMMs. Accordingly, both mouse and human LGGs displayed low frequency of TAMMs and PDGFRB^+^GCs, whereas grade III- and grade IV-like murine gliomas and human GBMs displayed high frequency of TAMMs and PDGFRB^+^GCs. Human grade III astrocytomas displayed a large heterogeneity in the accumulation of TAMMs and, therefore the frequency of PDGFRB^+^GCs also varied accordingly. TAMMs consist of a mixed population including tissue-resident microglia and macrophages that are ontogenetically different ([@bib3]). Microglia develop from embryonic yolk sac progenitor cells ([@bib13]) and only populate the brain during development. Thus, during adulthood microglia are maintained through survival and local proliferation ([@bib1], [@bib13]). Conversely, macrophages develop from hematopoietic precursors during embryonic development and establish stable resident populations in extracranial tissues ([@bib12]). The macrophages that populate GBMs are recruited to the tumor from the bone marrow ([@bib37]). The different origins of BMDMs and tissue-resident microglia result from distinct transcriptional and chromatin states, and the expression of markers in these cell populations may reflect different functions of tissue-resident microglia and BMDMs in GBMs ([@bib3]). Macrophages preferentially express CD49d ([@bib3]), whereas microglia show expression of Sall1 ([@bib48]). Interestingly, the majority of IBA1^+^ cells expressed Sall1 in mouse gliomas, pointing out that these cells were microglia and not macrophages. The induced and increased expression of PDGFRB and α-SMA in GCs, respectively, was ascribed to cell-to-cell contact with M2-polarized microglia but not with M2-polarized BMDMs.

Interestingly, *in vitro* co-culture of GSCs and M1- or M2-polarized microglia did not further augment stem cell marker expression, but instead downregulated oligodendrocyte progenitor marker *cnp*, whereas the astrocytoma marker *gfap* was markedly increased by M2-polarized microglia. GFAP is the hallmark in intermediate filaments and has been implicated in regulating the migratory capacity of GCs ([@bib32]). Hence, M2-polarized microglia induce not only high expression of PDGFRB but also high expression of GFAP. This in concert could possibly promote tumor cel0l migratory capacity. We speculate that microglia-GC-to-cell contact regulates PDGFRB transcription affecting any of the known transcription factors (NF-Y or Sp1) that promote PDGFRB transcription ([@bib20], [@bib33]). The underlying mechanisms whereby PDGFRB transcription is regulated by microglia deserve future investigations but lie outside the scope of the present investigation. In summary, these findings indicate that microglia and BMDM may affect GC behavior differently and deserve further investigation.

Limitations of the Study {#sec3.1}
------------------------

Currently, evidence is increasing about differences in function between microglia and macrophages. In concordance with our study, we show that microglia but not macrophages induce PDGFRB expression in GCs and thereby increase their migratory capacity. However, due to limitations of antibody combinations, it was not possible to use the two markers Sall1 and CD49d in the same immunofluorescence staining to distinguish between microglia and macrophages that are in direct contact with PDGFRB-expressing GCs. Hence elaborate lineage-tracing animal experiments are further needed to establish the differential role of macrophages and microglia in driving PDGFRB expression *in vivo*.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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